Many The Medicines Company(MDCO) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. The Medicines Company was Initiated by H.C. Wainwright on Dec 5, 2016 to Buy, Price Target of the shares are set at $57.
Company has reported several Insider transactions to the SEC, on Feb 7, 2017, William Bernard Oconnor (Chief Financial Officer) sold 25,833 shares at 46.48 per share price.On Dec 9, 2016, Christopher T Cox (EVP & Chief Corp. Dev. Officer) purchased 105,500 shares at 32.92 per share price.On Dec 8, 2016, Fredric N Eshelman (director) purchased 621,720 shares at 33.27 per share price.
The Medicines Company Last issued its quarterly earnings results on Oct 26, 2016. The company reported $-0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.41. Analyst had a consensus of $-1.05. The company had revenue of $37.60 million for the quarter, compared to analysts expectations of $36.66 million. The companys revenue was down -34.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.82 EPS.
The Medicines Company (NASDAQ:MDCO) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.13 by 8 Brokerage Firm. 7 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating.
The Medicines Company (NASDAQ:MDCO): 8 analysts have set the short term price target of The Medicines Company (NASDAQ:MDCO) at $52.63. The standard deviation of short term price target has been estimated at $7.52, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 65 and $39 respectively.
The Medicines Company (NASDAQ:MDCO) rose 1.72% or 0.87 points on Tuesday and made its way into the gainers of the day. After trading began at $50.51 the stock was seen hitting $51.54 as a peak level and $50.13 as the lowest level. The stock ended up at $51.52. The daily volume was measured at 1,953,113 shares. The 52-week high of the share price is $51.54 and the 52-week low is $28.51. The company has a market cap of $3,647 million.
Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.